AUG 21, 2014 6:45 AM PDT

Practical Considerations for the Clinical Interpretation of Germline Sequence Variants in the Era of NGS

Speaker
  • Clinical Molecular Genetics Fellow, Partners HealthCare Personalized Medicine
    Biography
      Dr. McLaughlin is an Assistant Laboratory Director at Partners HealthCare Personalized Medicine's Laboratory for Molecular Medicine. She received a B.S. in Diagnostic Molecular Science from Michigan State University and a Ph.D. in Human Genetics from the University of Michigan. She completed a Clinical Molecular Genetics Fellowship at the Harvard Medical School Genetics Training Program. Dr. McLaughlin's clinical interests focus on molecular diagnostic testing for inherited cardiomyopathies and pulmonary disorders and the implementation of exome and genome sequencing into the clinical laboratory. She is also interested in exploring incidental findings in individuals undergoing genomic sequencing and developing reporting formats that will aid in the integration of genomic sequencing into clinical medicine.

    Abstract

    The advent of next generation sequencing technologies has revolutionized the clinical genetics laboratory. Labs offering NGS are faced with an onslaught of sequence variants which must be interpreted with respect to the patients indication for testing. In this presentation we will review how to evaluate population frequencies, conservation analyses, pathogenicity predictions, splicing predictions, and published literature, and learn how to synthesize these data to determine variant classifications. We will also discuss important considerations and common pitfalls in the interpretation process, and learn how to construct variant interpretations for clinical reports.

    LEARNER OBJECTIVES:
    After completing this activity, the learner will be able to:
     

    • Assign a variant classification for a sequence variant
    • Construct a variant interpretation

    Show Resources
    You May Also Like
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    OCT 29, 2020 6:00 AM PDT
    C.E. CREDITS
    OCT 29, 2020 6:00 AM PDT
    Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    C.E. CREDITS
    This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
    SEP 03, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 03, 2020 9:00 AM PDT
    DATE: September 3, 2020 TIME: 09:00am PT, 12:00pm ET xxx Learning Objectives: xxx Webinars will be available for unlimited on-demand viewing after live event. LabRoots is approved as a provi...
    JUN 17, 2020 1:30 PM PDT
    C.E. CREDITS
    JUN 17, 2020 1:30 PM PDT
    Understanding the complex interplay between a pathogen and the host response is important to developing effective vaccines and therapeutics. The nCounter® Analysis System and GeoMx®...
    Loading Comments...
    Show Resources
    Attendees
    • See more